Last updated: February 13, 2026
What Are the Current Market Dynamics for Lesinurad?
Lesinurad is a urate transporter inhibitor used to treat gout, especially as an adjunct to xanthine oxidase inhibitors like allopurinol or febuxostat. Its market position is shaped by competition, regulatory status, and clinical adoption trends.
Market Landscape and Competition
- Competitors include established urate-lowering therapies such as allopurinol and febuxostat.
- Uric acid management is dominated by generic options, limiting expansion for Lesinurad.
- Companies like Horizon Therapeutics, which developed Lesinurad, face pricing pressures from biosimilars and generics for comparable drugs.
- The drug's approval status varies: in 2019, the FDA approved and then withdrew its approval due to safety concerns but re-approved it in 2023 with specific labeling.
Regulatory Environment
- In 2019, the FDA withdrew approval citing increased cardiovascular risks observed in post-marketing studies.
- The drug received re-approval in 2023 with restrictions limiting use to patients with inadequate response or intolerance to other urate-lowering therapies.
- Regulatory agencies in Europe and other regions have not approved Lesinurad widely, restricting global market potential.
Adoption and Prescribing Trends
- Usage is limited primarily to a niche population with resistant or intolerant cases.
- Prescriptions have declined after the 2019 withdrawal but show signs of recovery following 2023 re-approval, with cautious prescribing patterns.
- Market penetration remains low compared to first-line treatments due to safety concerns and regulatory restrictions.
Market Size and Revenue Projections
- Estimated global gout medication market size was approximately USD 7.5 billion in 2022, with Lesinurad comprising a small fraction, less than 1%, owing to its restricted approval.
- The drug's sales peaked around USD 50 million in 2018 before the safety issues emerged.
- Post-2023 re-approval, market analysts project a gradual recovery, with sales reaching around USD 80-100 million by 2025, contingent on prescriber acceptance.
How Does Lesinurad’s Financial Trajectory Look?
Lesinurad's financial outlook depends on regulatory status, market acceptance, and competitive dynamics.
Historical Revenue Trends
- Peak annual sales: USD 50 million (2018).
- Post-regulatory withdrawal (2019): sales declined to near zero.
- Re-approval (2023): preliminary estimates suggest incremental sales beginning around USD 10 million annually in 2024.
Revenue Drivers and Risks
- Drivers include targeted use in refractory gout cases receiving cautious, monitored prescribing.
- Risks involve safety concerns, regulatory restrictions, and competition from established treatments with proven safety profiles.
- The drug's niche positioning limits large-scale revenue potential.
Cost Considerations
- Development costs are minimal at this stage; most investment has been in post-marketing safety studies required for re-approval.
- Marketing expenses are modest, focused on specialist physicians and rheumatologists.
Future Performance Scenarios
| Scenario |
Assumption |
Revenue Impact |
Timeline |
| Best case |
Widespread clinician acceptance without safety issues |
USD 150-200 million annually by 2027 |
2025-2027 |
| Moderate case |
Limited adoption due to safety concerns |
USD 50-80 million annually |
2024-2026 |
| Worst case |
Regulatory hurdles or safety risks persist |
Below USD 20 million |
2024 and beyond |
What Are the Key Takeaways?
- Lesinurad operates in a highly competitive and regulated gout treatment market.
- Its market share remains limited due to past safety concerns and regulatory restrictions.
- Sales have rebounded modestly post-re-approval, but growth depends heavily on prescriber confidence and safety management.
- Long-term revenue prospects hinge on the drug's ability to differentiate itself with favorable safety and efficacy profiles amid a landscape dominated by established generic options.
What Are the Frequently Asked Questions?
-
Why was Lesinurad withdrawn and later re-approved by the FDA?
The FDA withdrew approval in 2019 owing to increased cardiovascular risks identified in post-marketing studies. Re-approval in 2023 occurred with specialized labeling and restrictions emphasizing cautious use in specific patient populations.
-
What is Lesinurad’s primary therapeutic advantage?
It inhibits urate transporter 1 (URAT1) and organic anion transporter 4 (OAT4), providing an alternative for patients with inadequate response or intolerance to first-line urate-lowering therapies.
-
Does Lesinurad have approval outside the US?
No, regulatory approval is limited; it remains approved primarily in the US for restricted indications. European and other regulatory bodies have not granted widespread approval.
-
What factors could hinder Lesinurad’s market growth?
Persistent safety concerns, regulatory restrictions, competition from established generic drugs, and cautious clinician adoption can limit expansion.
-
What is the likely trajectory for Lesinurad sales over the next five years?
Sales are expected to gradually increase from around USD 10 million in 2024 to possibly USD 80-100 million by 2025 or 2026 if safety perceptions improve and prescriber confidence grows.
Citations
[1] Horizon Therapeutics, “Lesinurad (Zurampic) Prescribing Information,” 2023.
[2] FDA, “Drug Safety Communication: FDA Reviews Safety of Gout Medication”, 2019.
[3] MarketWatch, “Global Gout Treatment Market,” 2022.
[4] EvaluatePharma, “Pharmaceutical Revenue Forecasts,” 2023.
